Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW. Plevris N, et al. Among authors: lees cw. J Crohns Colitis. 2019 Sep 19;13(9):1111-1120. doi: 10.1093/ecco-jcc/jjz042. J Crohns Colitis. 2019. PMID: 30768123
The use of adalimumab in the management of refractory Crohn's disease.
Ho GT, Smith L, Aitken S, Lee HM, Ting T, Fennell J, Lees CW, Palmer KR, Penman ID, Shand AG, Arnott ID, Satsangi J. Ho GT, et al. Among authors: lees cw. Aliment Pharmacol Ther. 2008 Feb 15;27(4):308-15. doi: 10.1111/j.1365-2036.2007.03583.x. Epub 2007 Dec 7. Aliment Pharmacol Ther. 2008. PMID: 18081730 Free article. Clinical Trial.
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.
Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR, Wilson DC, Arnott ID, Satsangi J. Lees CW, et al. Aliment Pharmacol Ther. 2009 Feb 1;29(3):286-97. doi: 10.1111/j.1365-2036.2008.03882.x. Aliment Pharmacol Ther. 2009. PMID: 19132970 Free article.
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008).
Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Hare NC, Wilson JA, Boulton-Jones R, Priest M, Watts DA, Shand AG, Arnott ID, Russell RK, Wilson DC, Morris AJ, Satsangi J. Ho GT, et al. Among authors: lees cw. Aliment Pharmacol Ther. 2009 Mar 1;29(5):527-34. doi: 10.1111/j.1365-2036.2008.03919.x. Aliment Pharmacol Ther. 2009. PMID: 19183339 Free article.
Letter: faecal calprotectin and lactoferrin - accurate biomarkers in post-operative Crohn's disease - authors' reply. Letter: biologic therapies are effective for prevention of post-operative Crohn's disease recurrence - authors' reply.
Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. Jones GR, et al. Among authors: lees cw. Aliment Pharmacol Ther. 2014 Aug;40(3):323. doi: 10.1111/apt.12848. Aliment Pharmacol Ther. 2014. PMID: 25040750 Free article. No abstract available.
174 results